Language selection

Search

Details for: MINT-KETOROLAC

Company: MINT PHARMACEUTICALS INC

DIN DIN name Active Ingredient(s) Strength Dosage Form Route of Administration
02461455MINT-KETOROLACKETOROLAC TROMETHAMINE10 MGTABLETORAL
Search Reported Side Effects Report a Side Effect

Consumer Information

This information was provided by the drug’s manufacturer when this drug product was approved for sale in Canada. It is designed for consumers and care givers. It is a summary of information about the drug and will not tell you everything about the drug. Contact your doctor or pharmacist if you have any questions about the drug.

What the medication is used for

Your health care provider has prescribed MINT-KETOROLAC tablets for you for one or more of the following medical conditions:

  • for short-term use as pain relief after surgery, after labour or after injury causing muscle or joint pain (not to exceed 5 days for post-surgical patients or 7 days for patients with musculoskeletal pain)
What it does

MINT-KETOROLAC (ketorolac tromethamine), as a non-steroidal anti-inflammatory drug (NSAID), can reduce the chemicals produced by your body which cause pain and swelling.

MINT-KETOROLAC, as a non-steroidal anti-inflammatory drug (NSAID), does NOT cure your illness or prevent it from getting worse. MINT-KETOROLAC only can relieve pain and reduce swelling as long as you continue to take it.

When it should not be used

DO NOT TAKE MINT-KETOROLAC if you have any of the following medical conditions:

  • have had or are planning to have heart bypass surgery
  • have severe, uncontrolled heart failure
  • have bleeding in the brain or other bleeding disorders
  • are at 28 weeks of pregnancy or more
  • are in labour and delivery
  • are breastfeeding or planning to breastfeed
  • are allergic to ASA (Acetylsalicylic Acid), other NSAIDs (Non-steroidal Anti-Inflammatory Drugs), MINTKETOROLAC or its ingredients
  • have active ulcer or bleeding from the stomach or gut
  • have inflammatory bowel disease (Crohn’s Disease or Ulcerative Colitis)
  • have liver or kidney disease
  • have high potassium in the blood
  • are currently using probenecid or oxpentifylline
  • are having central nervous system injection e.g. epidural, brain or spinal administration
  • are going into have any major surgery
  • are using other NSAIDs

Patients who took a drug in the same class as ketorolac tromethamine after a type of heart surgery (coronary artery bypass grafting (CABG)) were more likely to have heart attacks, strokes, blood clots in the leg(s) or lung(s), and infections or other complicationsthan those who did NOT take that drug.

MINT-KETOROLAC should NOT be used in patients under 18 years of age since the safety and effectiveness have NOT been established.

What the medicinal ingredient is

ketorolac tromethamine

What the non-medicinal ingredients are

MINT-KETOROLAC tablets: microcrystalline cellulose, lactose monohydrate, magnesium stearate, hypromellose, titanium dioxide, macrogol 4000.

What dosage form it comes in

MINT-KETOROLAC is available as: tablets (10 mg).

Warnings and precautions

Serious Warnings and Precautions

If you have, or previously had, any of the following medical conditions, see your health care provider to discuss treatment options other than MINTKETOROLAC:

  • Heart Attack or Angina
  • Stroke or Mini-stroke
  • Loss of Vision
  • Current Pregnancy (less than 28 weeks)
  • Congestive Heart Failure

Before taking this medication, tell your health care provider if you have any of the following:

  • High blood pressure
  • High cholesterol
  • Diabetes mellitus or on a low sugar diet
  • Thickening or hardening of your artery walls (Atherosclerosis)
  • Poor circulation to your extremities
  • Smoker or ex-smoker
  • Kidney disease or urine problems
  • Previous ulcer or bleeding from the stomach or gut
  • Previous bleeding in the brain
  • Bleeding problems
  • Liver, biliary, pancreatic or renal problems
  • Family history of allergy to NSAIDs, such as acetylsalicylic acid (ASA), celecoxib, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, rofecoxib, sulindac, tenoxicam, tiaprofenic acid, tolmetin, or valdecoxib (NOT a complete list)
  • Family history of asthma, nasal polyps, long-term swelling of the sinus (chronic sinusitis) or hives
  • Family history of allergy to sulfonamide drugs (if applicable)
  • Any other medical problem

Also, before taking this medication, tell your health care provider if you are planning to get pregnant.

While taking this medication:

  • tell any other doctor, dentist, pharmacist or other health care professional that you see, that you are taking this medication, especially if you are planning to have heart surgery;
  • do NOT drink alcoholic beverages while taking this medication because you would be more likely to develop stomach problems;
  • fertility may be decreased. The use of MINT-KETOROLAC is not recommended in women trying to get pregnant. In women who have difficulty conceiving, stopping MINT-KETOROLAC should be considered.
Interactions with this medication

Talk to your health care provider and pharmacist if you are taking any other medication (prescription or non-prescription) such as any of the following (NOT a complete list):

  • Acetylsalicylic Acid (ASA) or other NSAIDs
    • e.g. ASA, celecoxib, diclofenac, ibuprofen, indomethacin, ketorolac, meloxicam, naproxen)
  • Antacids
  • Antidepressants
    • Selective Serotonin Reuptake Inhibitors (SSRIs)
      • e.g. citalopram, fluoxetine, paroxetine, sertraline
  • Blood pressure medications
    • ACE (angiotensin converting enzyme) inhibitors
      • e.g. enalapril, lisinopril, perindopril, ramipril
    • ARBs (angiotensin II receptor blockers)
      • e.g. candesartan, irbesartan, losartan, valsartan
  • Blood thinners
    • e.g. warfarin, ASA, clopidogrel
  • Corticosteroids(including glucocorticoids)
    • e.g. prednisone
  • Cyclosporin
  • Digoxin
  • Diuretics
    • e.g. furosemide, hydrochlorothiazide
  • Lithium
  • Methotrexate
  • Morphine
  • Oxpentifylline
  • Probenacid

Your health care provider may prescribe low dose ASA (acetylsalicylic acid) as a blood thinner to reduce your risk of having a heart attack or stroke while you are taking MINTKETOROLAC. Take only the amount of ASA prescribed by your health care provider. You are more likely to upset or damage your stomach if you take both MINT-KETOROLAC and ASA than if you took MINT-KETOROLAC alone.

Proper use of this medication

MINT-KETOROLAC Tablets

Usual dose (18-65 years of age):

Medical Condition Starting Dose Maximum Dose (per day) Maximum Duration of Treatment (days)
Post-Surgical Pain or post-partum uterine cramping pain 10 mg every 4 to 6 hours as required Doses exceeding 40 mg per day are not recommended 5 days
Musculoskeletal Pain 10 mg every 4 to 6 hours as required Doses exceeding 40 mg per day are not recommended 7 days

Take MINT-KETOROLAC only as directed by your health care provider. Do NOT take more of it, do NOT take it more often and do NOT take it for a longer period of time than your health care provider recommended. If possible, you should take the lowest dose of this medication for the shortest time period. Taking too much MINT-KETOROLAC may increase your chances of unwanted and sometimes dangerous side effects, especially if you are elderly, have other diseases or take other medications.

In general, MINT-KETOROLAC should not be used for more than 7 days. If a longer period is considered, see your health care provider regularly to discuss whether this medicine is working for you and if it is causing you any unwanted effects.

This medication has been prescribed specifically for you. Do NOT give it to anyone else. It may harm them, even if their symptoms seem to be similar to yours.

MINT-KETOROLAC is NOT recommended for use in patients under 18 years of age since safety and effectiveness have NOT been established.

To lessen stomach upset, take MINT-KETOROLAC immediately after a meal or with food or milk. However, the presence of food in the stomach may delay the onset of pain relief. If stomach upset (indigestion, nausea, vomiting, stomach pain or diarrhea) occurs and continues, contact your doctor.

You should remain standing or sitting upright (i.e. do not lie down) for about 15-30 minutes after taking the medicine. This helps to prevent irritation that may lead to trouble swallowing.

Missed Dose

The missed dose should be taken as soon as remembered, and then the regular dosing schedule should be continued. Two doses of MINT-KETOROLAC should not be taken at the same time.

Overdose

In case of drug overdose, contact a healthcare practitioner, hospital emergency department, or regional poison control centre, even if there are no symptoms.
Side effects and what to do about them

MINT-KETOROLAC may cause some side effects, especially when used for a long time or in large doses. When these side effects occur, you may require medical attention. Report all symptoms or side effects to your health care provider.

MINT-KETOROLAC may cause you to become drowsy or tired. Be careful about driving or participating in activities that require you to be alert. If you become drowsy, dizzy or light-headed after taking MINT-KETOROLAC, do NOT drive or operate machinery.

MINT-KETOROLAC may cause you to become more sensitive to sunlight. Any exposure to sunlight or sunlamps may cause sunburn, skin blisters, skin rash, redness, itching or discolouration, or vision changes. If you have a reaction from the sun, check with your health care provider.

Check with your health care provider IMMEDIATELY if you develop chills, fever, muscle aches or pains, or other flu-like symptoms, especially if they occur before or together with a skin rash. These symptoms may be the first signs of a SERIOUS ALLERGIC REACTION to this medication.

Serious side effects, how often they happen and what to do about them
Symptom / effect STOP taking MINTKETOROLAC and get emergency medical attention IMMEDIATELY STOP taking MINTKETOROLAC and talk to your physician or pharmacist
Bloody or black tarry stools  
Shortness of breath, wheezing, any trouble breathing or chest tightness  
Skin rash, hives, swelling or itching  
Blurred vision, or any visual disturbance  
Any change in the amount or colour of your urine (red or brown)  
Any pain or difficulty experienced while urinating  
Swelling of the feet, lower legs, weight gain  
Vomiting or persistent indigestion, nausea, stomach pain or diarrhea  
Yellow discolouration of the skin or eyes, with or without itchy skin  
Malaise, fatigue, loss of appetite  
Headaches, stiff neck  
Mental confusion, depression  
Dizziness, lightheadedness  
Hearing problems  

This is not a complete list of side effects. If you develop any other symptoms while taking MINT-KETOROLAC, see your health care provider.

How to store

Store MINT-KETOROLAC at room temperature (15-30°C) away from light and moisture.

Do NOT keep outdated medicine or medicine no longer needed. Any outdated or unused medicine should be returned to your pharmacist

Keep out of sight and reach of children.

Reporting side effects

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following three ways:

  • Report online at www.healthcanada.gc.ca/medeffect
  • Call toll-free at 1-866-234-2345
  • Complete a Canada Vigilance Reporting Form and:
    • Fax toll-free to 1-866-678-6789, or
    • Mail to:
      Canada Vigilance Program
      Health Canada
      Postal Locator 0701E
      Ottawa ON K1A 0K9

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

More information

This document plus the full product monograph, prepared for health professionals can be found at:
http://www.mintpharmaceuticals.com
or by contacting the sponsor, Mint Pharmaceuticals Inc., at:
1.877.398.9696.

This leaflet was prepared by
Mint Pharmaceuticals Inc.
Mississauga, Ontario L5T 1J6
Last revised: February 6, 2017

Date modified: